v3.26.1
Note 13 - Net Loss per Share (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2026

 

 

2025

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(13,909

)

 

$

(26,908

)

Series B Convertible Preferred Stock dividends earned

 

 

(9,719

)

 

 

(9,110

)

Net loss attributable to Lucid Diagnostics Inc. common stockholders

 

$

(23,628

)

 

$

(36,018

)

 

 

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

140,096,782

 

 

 

68,796,392

 

 

 

 

 

 

 

 

 

 

Net loss per share (1)

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.17

)

 

$

(0.52

)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

 

 

March 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

12,353,542

 

 

 

9,956,444

 

Unvested restricted stock awards

 

 

12,295,240

 

 

 

6,584,240

 

Shares held in abeyance

 

 

13,294,267

 

 

 

 

Preferred stock

 

 

16,823,764

 

 

 

49,607,115

 

Total

 

 

54,766,813

 

 

 

66,147,799